Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2025-09-08 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a 'Déclaration des transactions sur actions propres' (Declaration of transactions in own shares) for Sanofi. It provides a detailed, transaction-by-transaction breakdown of share repurchases conducted between September 1, 2025, and September 5, 2025, including timestamps, prices, quantities, and market identifiers. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-09-08 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (01 September 2025 to 05 September 2025). It includes detailed transaction logs, including broker information, transaction times, prices, and volumes, which is characteristic of a 'Transaction in Own Shares' filing. This aligns perfectly with the definition for the POS category.
2025-09-08 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release dated September 4, 2025, about a clinical study result, and the document length is short (1373 characters). The document does not contain detailed financial statements or substantive financial data but rather announces the press release. According to the 'Menu vs Meal' rule, this is an announcement of information rather than the full report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-09-04 English
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing positive clinical trial results (COAST 1 phase 3 study) for a drug candidate (amlitelimab). It details study endpoints, efficacy data, and safety profiles. This type of corporate announcement regarding R&D progress and clinical trial outcomes is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into specific categories like financial reports, dividend notices, or M&A activity.
2025-09-04 English
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteint
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing positive Phase 3 clinical trial results for their drug 'amlitelimab'. It details the study methodology, efficacy data, and safety profile. This type of document, which provides updates on clinical trial progress and drug development, is classified as a Regulatory Filing (RNS) in the absence of a more specific category like 'Clinical Trial Results' (which is not in the provided list). It is not an Annual Report, Earnings Release, or Investor Presentation, but rather a standard corporate announcement regarding R&D milestones.
2025-09-04 French
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC to provide current information. It references a press release dated August 29, 2025, about a product approval, but does not contain financial statements or detailed financial data. The document length is short (1314 characters), and it primarily serves as a regulatory update with an attached press release. According to the rules, such filings that provide regulatory announcements or miscellaneous information without substantive financial data should be classified as Regulatory Filings (RNS).
2025-09-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.